Literature DB >> 4723801

The bradykininase activities of extracts of dog lung.

V A Alabaster, Y S Bakhle.   

Abstract

1. Homogenates of dog lungs freed from blood inactivate bradykinin. The bradykininase activity is present in soluble and particulate subcellular fractions.2. The fraction with the highest relative specific activity is that sedimenting between 8,700 g and 78,000 g. This fraction has been studied in more detail.3. There is evidence for two bradykinin inactivating enzymes in this fraction with apparent K(m) values of 7.5 muM and 120 muM.4. The bradykininase activity is not dependent on the concentration of chloride ion.5. The bradykininase activity is inhibited by EDTA, 2:3-dimercaptopropanol, nickel ions and some of the peptides from the venom of Bothrops jararaca and of Agkistrodon halys blomhoffii but not by 2-mercaptoethanol or N-ethylamaleimide.6. Angiotensin II in either 15 or 170 mM chloride ion is not an inhibitor of bradykininase activity but angiotensin I at either chloride concentration is an inhibitor. It is proposed that chloride is not necessary for binding of angiotensin I to converting enzyme but is necessary to ensure the correct orientation of substrate for hydrolysis to proceed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4723801      PMCID: PMC1776064          DOI: 10.1111/j.1476-5381.1973.tb08207.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE.

Authors:  H P RANG
Journal:  Br J Pharmacol Chemother       Date:  1964-04

2.  Characteristics of the angiotensin I converting enzyme from dog lung.

Authors:  Y S Bakhle; A M Reynard
Journal:  Nat New Biol       Date:  1971-02-10

3.  Carboxycathepsin--a key regulatory component of two physiological systems involved in regulation of blood pressure.

Authors:  Y E Elisseeva; V N Orekhovich; L V Pavlikhina; L P Alexeenko
Journal:  Clin Chim Acta       Date:  1971-02       Impact factor: 3.786

4.  Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C.

Authors:  H Kato; T Suzuki
Journal:  Biochemistry       Date:  1971-03-16       Impact factor: 3.162

5.  Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme.

Authors:  S H Ferreira; L H Greene; V A Alabaster; Y S Bakhle; J R Vane
Journal:  Nature       Date:  1970-01-24       Impact factor: 49.962

6.  Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung.

Authors:  Y S Bakhle
Journal:  Nature       Date:  1968-11-30       Impact factor: 49.962

7.  Subcellular distribution and properties of the bradykinin inactivation system in rabbit brain homogenates.

Authors:  A C Camargo; F G Graeff
Journal:  Biochem Pharmacol       Date:  1969-02       Impact factor: 5.858

8.  Pharmacological significances of peptidase and proteinase in the brain. I. Enzymatic inactivation of bradykinin in rat brain.

Authors:  H Iwata; T Shikimi; T Oka
Journal:  Biochem Pharmacol       Date:  1969-01       Impact factor: 5.858

9.  Second kininase in human blood plasma.

Authors:  H Y Yang; E G Erdös
Journal:  Nature       Date:  1967-09-23       Impact factor: 49.962

10.  Action of bradykinin potentiating factor (BPF) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestines.

Authors:  A Camargo; S H Ferreira
Journal:  Br J Pharmacol       Date:  1971-06       Impact factor: 8.739

View more
  2 in total

1.  Hydrolysis of bradykinin and its higher homologues by angiotensin-converting enzyme.

Authors:  F Dorer; J W Ryan; J M Stewart
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

2.  The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition.

Authors:  J M Vinci; J R Gill; R E Bowden; J J Pisano; J L Izzo; N Radfar; A A Taylor; R M Zusman; F C Bartter; H R Keiser
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.